| ACE Inhibitor Reduces ESRD Risk Among Obese Patients - Renal and Urology News |
|
|
Renal and Urology News Ramipril can essentially abolish the excess risk for end-stage renal disease (ESRD) seen in obese persons with chronic kidney disease (CKD), according to a post hoc analysis of the Ramipril Efficacy in Nephropathy (REIN) trial. |